Vision Formulation Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 26.66%
- Ebitda 45.93%
- Net Worth -30.01%
- Total Assets -48.28%
About Vision Formulation Pharma
Vision Formulation Pharma Private Limited (VFPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 October 2014 and has a history of Ten years and four months. Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anuj Aggarwal and Nishant Aggarwal serve as directors at the Company.
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51101UP2014PTC066537
- Company No.
066537
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Oct 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Vision Formulation Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anuj Aggarwal  | Director | 20-Jan-2015 | Current |
| Nishant Aggarwal | Director | 26-Jun-2024 | Current |
Financial Performance of Vision Formulation Pharma.
Vision Formulation Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 26.66% increase in profit. The company's net worth observed a substantial decline by a decrease of 30.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vision Formulation Pharma?
In 2019, Vision Formulation Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bholanathpansari Ayurved Private LimitedAnuj Aggarwal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vision Formulation Pharma?
Unlock and access historical data on people associated with Vision Formulation Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vision Formulation Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vision Formulation Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
